Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

David Alan Frank, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by David Frank and Sara Walker.
Connection Strength

6.582
  1. Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch? Oncoscience. 2015; 2(11):912.
    View in: PubMed
    Score: 0.658
  2. STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b. Cancers (Basel). 2014 Apr 23; 6(2):958-68.
    View in: PubMed
    Score: 0.590
  3. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol Cell Biol. 2013 Aug; 33(15):2879-90.
    View in: PubMed
    Score: 0.554
  4. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol. 2014 Jan 25; 382(1):616-621.
    View in: PubMed
    Score: 0.547
  5. Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets. JAKSTAT. 2012 Oct 01; 1(4):292-9.
    View in: PubMed
    Score: 0.529
  6. STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents. Mol Cell Pharmacol. 2011 Jan 01; 3(1):13-19.
    View in: PubMed
    Score: 0.469
  7. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol. 2010 Nov; 78(5):903-8.
    View in: PubMed
    Score: 0.456
  8. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009 Jun; 7(6):966-76.
    View in: PubMed
    Score: 0.420
  9. Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98.
    View in: PubMed
    Score: 0.235
  10. CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3. Neoplasia. 2020 01; 22(1):47-59.
    View in: PubMed
    Score: 0.217
  11. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018 12 11; 2(23):3428-3442.
    View in: PubMed
    Score: 0.203
  12. The STAT3 Target Gene TNFRSF1A Modulates the NF-?B Pathway in Breast Cancer Cells. Neoplasia. 2018 05; 20(5):489-498.
    View in: PubMed
    Score: 0.194
  13. Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer. Genes Cancer. 2015 Mar; 6(3-4):153-68.
    View in: PubMed
    Score: 0.156
  14. Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J Immunol. 2015 Apr 01; 194(7):3180-90.
    View in: PubMed
    Score: 0.156
  15. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-?B to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal. 2014 Jan 28; 7(310):ra11.
    View in: PubMed
    Score: 0.145
  16. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther. 2014 May; 13(5):1194-205.
    View in: PubMed
    Score: 0.145
  17. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11.
    View in: PubMed
    Score: 0.130
  18. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12):3421-9.
    View in: PubMed
    Score: 0.117
  19. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15; 112(13):5095-102.
    View in: PubMed
    Score: 0.100
  20. Identification of human STAT5-dependent gene regulatory elements based on interspecies homology. J Biol Chem. 2006 Sep 08; 281(36):26216-24.
    View in: PubMed
    Score: 0.086
  21. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem. 2004 Dec 24; 279(52):54724-30.
    View in: PubMed
    Score: 0.076
  22. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 Aug; 125(4):582-592.
    View in: PubMed
    Score: 0.060
  23. Retraction Note: Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation. Nature. 2020 07; 583(7814):154.
    View in: PubMed
    Score: 0.057
  24. Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-palmitoylation. Nature. 2019 09; 573(7772):139-143.
    View in: PubMed
    Score: 0.053
  25. Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts. Oncogenesis. 2019 Feb 22; 8(3):15.
    View in: PubMed
    Score: 0.052
  26. NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discov. 2016; 2:16030.
    View in: PubMed
    Score: 0.044
  27. Fold change of nuclear NF-?B determines TNF-induced transcription in single cells. Mol Cell. 2014 Mar 20; 53(6):867-79.
    View in: PubMed
    Score: 0.036
  28. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013 Feb; 45(2):131-2.
    View in: PubMed
    Score: 0.034
  29. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
    View in: PubMed
    Score: 0.033
  30. The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011 Jul; 121(7):2723-35.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.